Aviptadil is the emerging pharmacological therapy in ARDS. It is the injectable synthetic formulation of human vasoactive intestinal polypeptide (VIP). Oxyptadil is the first ever VIP introduced by Zuventus in the management of ARDS. With this, our goal is to provide patients with a chance to lead a healthy life.